Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3738 Breast neuroendocrine carcinoma – A case report

Introduction: Neuroendocrine breast tumors are a rare entity estimated at 0.1% of all breast tumors.

Conference:

Presenting Author:

Authors: Kaid M, Bengueddache A, Kehili H, Bennaoum A, Bereksi-Reguig F,

Keywords: breast neuroendocrine tumor,

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,

#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression

Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,

Keywords: neuroendocrine, estrogen, progesterone, clinical trial,

#2155 Menstrual Dysfunction in Women with Prolactinomas

Introduction: Hyperprolactinemia syndrome (HPS) is a set of symptoms with typical increase in serum prolactin accompanied by galactorrhea, hypogonadism and potential infertility

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Safarova M, Khalimova Z, Axmedova S, Issaeva S, Gumarova A,

Keywords: prolactinoma, hyperprolactinemia, dopamine agonists,

#1592 Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy

Introduction: WHO classification from 2003 defines primary neuroendocrine carcinomas (NEC) of the breast as a group of tumors with expression of neuroendocrine markers in more than 50% of tumor cells. In the current WHO classification this category is renamed to “carcinomas with neuroendocrine features” without defined clear-cut of the percentage of tumor cells positive for neuroendocrine markers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Demirovic A

Authors: Demirović A, Vranic S, Skenderi F, Peric Balja M, Ulamec M,

Keywords: breast cancer, special types, carcinoma with neuroendocrine features, neuroendocrine markers,